Daniel Gaudet


Dr. Gaudet is affiliated to the Department of Medicine, Université de Montréal (UdeM). He  is the scientific  director of the UdeM Community Genetic Medicine Center and its Clinical Lipidology and Rare Lipid Disorders Unit.

He is currently president and scientific director of ECOGENE-21, a non-for profit organization devoted to access to innovation in precision medicine. His main clinical and academic activities aim at investigating rare dyslipidemias and translating new knowledge issued from extreme phenotypes to more common forms of diseases.

Over the years, he has coordinated more than 200 studies involving the development of screening tools, technologies or therapies for severe dyslipidemias or related disorders, in collaboration with biotechs, pharmas,  or academic partners. He authored more than 300 scientific publications in peer-reviewed journals, including several tens in very highly rated Journals (NEJM, Lancet, Nature Medicine, Nature Genetics) as well as >500 scientific communications or book chapters.

COI Disclosure
Dr. Gaudet is an employee of Universite de Montreal. He reports professionnal relationship with Aegerion (Amryt), Akcea, Amgen, Novartis, Regeneron (Honoraria/ Expenses, Consulting/ Advisory Board and Funded Research), Esperion, Gemphire (Funded Research), Eli Lilly and Verve (Honoraria/ Expenses, Consulting/ Advisory Board).